TerminatedPhase 3NCT00006708
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- David G. Maloney, MD, PhDFred Hutchinson Cancer Center
- Intervention
- filgrastim(biological)
- Enrollment
- 7 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2000 – 2006
Study locations (30)
- MBCCOP - Gulf Coast, Mobile, Alabama, United States
- CCOP - Greater Phoenix, Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
- Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States
- Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
- Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006708 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic